NCT00976170 - Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2014

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

GC33(RO5137382)

IV administration at 6 escalating dose levels.

DRUG

Sorafenib

Oral administration at 400mg twice daily or 400mg once daily

Trial Locations (7)

California Pacific Medical Center, San Francisco

University of Miami, Miami

Memorial Sloan-Kettering Cancer Center, New York

University of North Carolina, Chapel Hill

National Cheng Kung University Hospital, Tainan City

National Taiwan Univercity Hospital, Taipei

Fox Chase Cancer Center, Philadelphia